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Abstract
Introduction of a conjugated vaccine against encapsulated Haemophilus inﬂuenzae type b (Hib) has led to a dramatic reduction of invasive
Hib disease. However, an increasing incidence of invasive disease by H. inﬂuenzae non-type b has recently been reported. Non-type b
strains have been suggested to be opportunists in an invasive context, but information on clinical consequences and related medical con-
ditions is scarce. In this retrospective study, all H. inﬂuenzae isolates (n = 410) from blood and cerebrospinal ﬂuid in three metropolitan
Swedish regions between 1997 and 2009 from a population of approximately 3 million individuals were identiﬁed. All available isolates
were serotyped by PCR (n = 250). We observed a statistically signiﬁcant increase in the incidence of invasive H. inﬂuenzae disease,
ascribed to non-typeable H. inﬂuenzae (NTHi) and encapsulated strains type f (Hif) in mainly individuals >60 years of age. The medical
reports from a subset of 136 cases of invasive Haemophilus disease revealed that 48% of invasive NTHi cases and 59% of invasive Hif
cases, respectively, met the criteria of severe sepsis or septic shock according to the ACCP/SCCM classiﬁcation of sepsis grading. One-
ﬁfth of invasive NTHi cases and more than one-third of invasive Hif cases were admitted to intensive care units. Only 37% of patients
with invasive non-type b disease had evidence of immunocompromise, of which conditions related to impaired humoral immunity was
the most common. The clinical burden of invasive non-type b H. inﬂuenzae disease, measured as days of hospitalization/100 000 individu-
als at risk and year, increased signiﬁcantly throughout the study period.
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Introduction
Haemophilus inﬂuenzae is a frequent colonizer of the human
respiratory tract. The species is subdivided into non-encap-
sulated and encapsulated strains that are typed based upon
the presence of one of six antigenically distinct polysaccha-
ride capsules designated a to f [1]. Strains that do not have a
capsule are denoted non-typeable H. inﬂuenzae (NTHi). The
carriage rates of NTHi in healthy pre-school children are as
high as 65% [2], suggesting that NTHi is usually a commensal.
However, NTHi frequently causes otitis media and pneumo-
nia in children [3], and is the most common bacterial ﬁnding
in exacerbations of chronic obstructive pulmonary disease
[4]. Invasive NTHi cases are suggested to be opportunistic
infections [3], even though information on correlated medical
conditions is scarce.
Invasive disease by H. inﬂuenzae has historically been ana-
logous with disease by encapsulated strain type b (Hib), a
feared cause of sepsis, epiglottitis and meningitis in children
and occasionally in adults [5]. In the early 1990s, the conju-
gated Hib vaccine was introduced in most countries in the
Western World, and a dramatically reduced incidence
of invasive Hib disease occurred [6]. The incidence of
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bacteraemia caused by Hib in Sweden in the late 1980s was
approximately 30/100 000 children, and these numbers had
decreased 10-fold by 1994 [7]. The current Swedish Hib vac-
cine coverage rate is 99%.
Several reports on the epidemiology of invasive non-type
b Haemophilus disease in the post-Hib-vaccine era have been
published in recent years [8–13]. Indications of a rising inci-
dence of invasive non-type b disease have been observed in
North America [8,9,13,14]. The status in Europe is less clear,
but a recent study encompassing surveillance data from 14
European countries between 1996 and 2006 showed a small
but signiﬁcant increase in incidence of invasive NTHi disease
[15]. In contrast, a German study covering 1998–2005 did
not reveal any increase in invasive non-type b disease [16].
Even though invasive Hib disease has been successfully
repressed following the widespread introduction of the Hib
vaccine, invasive disease by H. inﬂuenzae non-type b remains
a clinical challenge.
Most epidemiological reports on invasive non-type b H. in-
ﬂuenzae disease lack information on disease severity. Further-
more, although suggested as an opportunistic disease, there
is little information on underlying conditions associated with
invasive non-type b cases. In the present retrospective study
we show that invasive disease caused by non-type b strains
of H. inﬂuenzae has increased in incidence in Sweden in the
period 1997–2009, that it readily affects individuals who are
otherwise in good health, and is often clinically severe.
Materials and Methods
Bacterial strains and culture conditions
The H. inﬂuenzae collection comprised clinical isolates from
three densely populated regions in Sweden: Stockholm,
Gothenburg and Ska˚ne county (see Supplementary material
Fig. S1). All saved isolates from blood and cerebrospinal
ﬂuid (CSF) had been stored at )70C. All available isolates
(n = 250) were grown on chocolate blood agar and incubated
at 35C in a humid atmosphere containing 5% CO2.
DNA preparation and molecular typing
To amplify the capsule transport gene, a bexA colony PCR
was performed on all available strains (n = 250) [17]. To
increase the sensitivity, all strains were also screened for
bexB using primers 5¢-TTGTGCCTGTGCTGGAAGGT
TATG-3¢ and 5¢-GGTGATTAACGCGTTGCTTATGCG-3¢.
Strains positive for bexA and/or bexB were further tested
using speciﬁc primers against types b, a, d and f, c, and e cap
loci in sequential order. Whenever a strain had previously
been typed by PCR, the result was included in the analysis in
case the strain was not available (n = 21) for contemporary
PCR testing. Results from serotyping by agglutination with
antisera were not used because this method is considered
inferior in speciﬁcity [18]. The caspsule gene was assumed to
be expressed in all isolates carrying the bex and cap loci. The
strict commensal Haemophilus haemolyticus can be indistin-
guishable from H. inﬂuenzae by standard bacteriological tech-
niques so all isolates were tested by a slightly modiﬁed
version of the PCR described by Murphy et al. [19]. Instead
of a nested PCR, an initial PCR with primers denoted as
16S3¢ and 16SNor [19] was performed. If a product of the
correct size was not obtained, isolates (n = 6) were sub-
jected to 16S rRNA sequencing.
Patient data
Basic epidemiological data such as culture date, age and gen-
der were available for all strains. Medical reports from all
patients in the county of Ska˚ne (n = 136) were studied, and
information on immunocompromise, sepsis severity, duration
of stay in hospital, intensive care treatment and mortality
was registered. Sepsis severity was deﬁned according to the
American College of Chest Physicians/Society of Critical
Care Medicine (ACCP/SCCM) consensus document [20]. As
a result of the retrospective nature of the study, not all
medical reports contained complete information on all
ACCP/SCCM criteria. Only objective and registered parame-
ters were included in the analysis. Meningitis/epiglottitis with
sepsis are life-threatening conditions, so these cases were
considered severe regardless of other criteria. Immuno-
compromise was deﬁned according to a deﬁnition adapted
from the Merck Manual [21]; see Supplementary material
Table S1.
Data sorting and estimates of population at risk
All blood and CSF samples taken in the included geographi-
cal areas were processed by four central laboratories that
kept complete back records of invasive isolates by a data-
base (three laboratories) or by a written list (one labora-
tory). All recorded H. inﬂuenzae isolates from blood and
CSF were included in the study. Because of variations in
storage routines, not all isolates had been saved, and only a
few had been previously serotyped by PCR. Therefore, two
separate analyses were performed. The primary analysis was
based on all recorded strains regardless of serotype, and
the secondary analysis was based only on years when at
least half of the isolates from each laboratory could be or
had been serotyped by PCR (n = 285). The laboratories
were Malmo¨ (all years 1997–2009), Lund (2004–2009),
Gothenburg O¨stra Laboratory (1999–2009), Gothenburg
Sahlgrenska Laboratory (1997–2000, 2003–2004 and
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2007–2009) and Karolinska Laboratory Solna, Stockholm
(1998, 2000 and 2004–2008). Any recorded strain from an
included year in the secondary analysis that could not be
retrieved was registered as ‘not analysed (N/A)’ (n = 17)
and included in the subsequent analysis. Each geographical
area had tertiary-care units, where patients referred from
outside the area were treated. The addresses of patients
(n = 11) with invasive Haemophilus disease at tertiary units
were checked, and six of these could be conﬁrmed as resi-
dents of the included geographical areas. For the remaining
ﬁve patients, no information was available on living
addresses at the time of sepsis. For each year in the study,
two estimates of population at risk were deﬁned (Table 1);
one estimate for each of the described analyses. Population
data were collected from the Swedish central statistics
agency (http://www.ssd.scb.se). The estimates of population
considered the population by geographical area served by
each laboratory unit and year. In Lund and Malmo¨, the
areas of Helsingborg and Kristianstad were added during
the course of the study. In Stockholm, the population base
was the northern part (with the addition of St Go¨rans hos-
pital in 1997 and 1998) for adults and the greater area of
Stockholm for children. In Gothenburg, the inner city was
the population base with the addition of North Bohusla¨n
from 2001. The numbers for Stockholm and Gothenburg
were double-checked by comparing the numbers of visits to
the emergency-care units of the included hospitals with the
total emergency-care visits in the greater counties (from
which an exact population estimate was known each year).
Statistical analysis
Assuming a linear relation of data, trend tests using linear
regression analysis were performed on all data using PAWS
statistic 18.0.
Ethical approval
This study was approved by the regional ethical committee
for medical research in Lund, Sweden (2009/536).
Results
Increasing incidence of invasive H. inﬂuenzae disease
Back records revealed 410 cases of invasive disease caused
by H. inﬂuenzae in the deﬁned geographical areas during the
years 1997–2009 (Table 1). The incidence varied from 0.5 (in
1998) to 1.7 (in 2007) cases per 100 000 individuals (Fig. 1a).
In the primary analysis, which included all recorded isolates
regardless of serotype, there was a signiﬁcantly increased
incidence (constant = 0.082, 95% CI 0.040–0.123, p £ 0.001).
In the secondary analysis, only regions and years where
>50% of isolates were typed by PCR (n = 285) were
included (Table 1). As shown in Fig. 1(b), NTHi accounted
for the majority (n = 191) of cases. The 77 encapsulated iso-
lates were deﬁned as Hib (n = 29), Hif (n = 44), Hie (n = 1),
or ‘encapsulated non-type b’ (n = 3). A statistically signiﬁcant
increase in invasive disease by NTHi (constant = 0.079, 95%
CI 0.046–0.111, p £0.001) and Hif (constant = 0.023, 95% CI
0.003–0.043, p 0.025) was observed, whereas the incidence








secondary analysiseNTHib Hibb Hifb Non-bc N/Ad
1997 25 (2) 4 2 1 1 1 2 407 000 1 102 000
1998 15 (3) 8 2 2 0 0 2 684 000 2 074 000
1999 16 (0) 3 0 1 0 1 2 433 000 1 222 000
2000 17 (2) 6 0 2 0 2 2 507 000 1 981 000
2001 20 (2) 3 0 0 0 1 2 720 000 801 000
2002 35 (5) 8 1 0 0 1 2 753 000 810 000
2003 31 (3) 6 1 0 0 1 2 774 000 1 352 000
2004 46 (4) 26 10 2 2 6 2 795 000 2 795 000
2005 35 (4) 20 2 3 0 1 2 815 000 2 274 000
2006 32 (4) 16 3 5 1 1 2 844 000 2 299 000
2007 49 (1) 35 4 8 0 2 2 874 000 2 874 000
2008 48 (5) 30 2 16 0 0 2 909 000 2 909 000
2009 41 (3) 26 2 4 0 0 2 935 000 2 164 000
Total 410 (38) 191 29 44 4 17
aAll invasive H. inﬂuenzae isolates during the study period and included in the primary analysis. Cerebrospinal ﬂuid (CSF) isolates among the total number are given within
parantheses.
bNumbers of isolates typed by PCR: NTHi, non-typeable H. inﬂuenzae; Hib, H. inﬂuenzae type b; Hif, H. inﬂuenzae type f.
cComprising ‘encapsulated non-type b’ strains that were previously typed by a capB PCR using bexA as target. These strains had not been stored and were consequently not
available for further analysis. The only H. inﬂuenzae type e isolate (from 2006) is also included here.
dN/A; not analysed. These isolates were not available for PCR serotyping, but were included in the secondary analysis as described in Materials and Methods.
ePopulation base including only years when >50% of strains were serotyped by PCR at each laboratory unit. This particular population out of the total population base was
used in the secondary analysis.
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of Hib disease was unchanged during the study period. No
H. haemolyticus isolate was identiﬁed in the material.
Increased incidence of invasive H. inﬂuenzae in individuals
>60 years of age
The median ages of Hib, Hif and NTHi case patients were
38, 60 and 71 years, respectively. Only 11 of the 410 cases
(3%) occurred in neonates (<28 days of age). NTHi was pre-
dominant in all age groups, including children <5 years of
age. Based on an age-stratiﬁed population at risk (Fig. 2), it
was evident that the observed increase of invasive H. inﬂuen-
zae disease mainly occurred in individuals >60 years of age.
The increase in both age groups 60–80 years (constant =
0.212, 95%CI 0.098–0.326, p 0.002) and >80 years (con-
stant = 0.602, 95% CI 0.212–0.992, p 0.006) was statistically
signiﬁcant. No gender difference could be identiﬁed for any
of the subspecies.
High proportion of sepsis severity in non-type b
H. inﬂuenzae cases
When medical records were analysed in detail we found that
the most common clinical presentation of invasive non-type
b disease (in this context presence of bacteria in blood or
CSF) was pneumonia (70%) but a wide variety of other pre-
sentations such as meningitis, epiglottitis, soft tissue infec-
tions and cholangitis was seen. As many as 48% of NTHi
cases (n = 101) met the criteria of severe sepsis or septic
shock, and 20% were admitted to intensive care units
(Table 2). Interestingly, 62% of invasive NTHi cases occurred
in individuals without evidence of immunocompromise,
although one-third of these patients were >80 years of age.
The case mortality (within 28 days) was 8%, whereas the
1-year mortality of invasive NTHi cases was 29%. Hif gener-
ally caused severe disease; 59% of Hif cases (n = 22) met the
criteria of severe sepsis or septic shock, and 36% of cases
were admitted to intensive care units. The majority of inva-
sive Hif cases (68%) occurred in individuals without evidence
of immunocompromise, whereas <10% of patients were
(a)
(b)
FIG. 1. The incidence of invasive Haemophilus inﬂuenzae disease
increased signiﬁcantly during the years 1997–2009. (a) Total inci-
dence of invasive H. inﬂuenzae disease per 100 000 individuals and
year from the primary analysis (regardless of serotype) (n = 410).
The increase in incidence was statistically signiﬁcant (p £ 0.001). (b)
Results from the secondary analysis, comprising 285 deﬁned cases
are shown. The increase was statistically signiﬁcant (p 0.001 and
p 0.025 for non-typeable H. inﬂuenzae (NTHi) and H. inﬂuenzae type
f (Hif), respectively). Isolates (n = 17) that had not been saved or
previously deﬁned by PCR are indicated as not analysed (N/A).
Regardless of the hypothetical outcome of the 17 non-analysed
isolates, the increase of invasive NTHi disease remained statistically
signiﬁcant.
FIG. 2. The incidence per patient age group of invasive Haemophilus
inﬂuenzae disease per 100 000 age-group-sorted individuals at risk is
shown. The incidence increased signiﬁcantly in the age groups 60–
80 years and >80 years during the course of the study (p 0.002 and
p 0.006, respectively). When the results from PCR serotyping were
taken into account, the increase was mainly ascribed to non-typeable
H. inﬂuenzae (NTHi), but in part also to H. inﬂuenzae type f (Hif).
CMI Resman et al. Increasing incidence of sepsis with NTHi and Hif 1641
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>80 years of age. Case mortality for Hif was 14% and 1-year
mortality was 27%. Patients with invasive Hib infections
(n = 13) were included as a control group and 77% of these
patients met the criteria of severe sepsis/septic shock and
54% were admitted to an intensive care unit.
Increased clinical burden of invasive non-type b
H. inﬂuenzae
To monitor the clinical burden of invasive H. inﬂuenzae non-
type b disease, the demand for hospitalization days per year
and individual at risk was studied (Fig. 3; ﬁlled circles). A
statistically signiﬁcant increase of hospital days/100 000 indi-
viduals at risk was identiﬁed (Constant = 1.31, 95%
CI = 0.03–2.60, p 0.046). During the same time period, the
average duration of hospitalization per case of any bacterial
pneumonia or sepsis decreased in the same geographical area
(Fig. 3; black and grey bars, respectively). Hence, despite
shorter hospitalization periods for severe infections in gen-
eral, the required days of hospitalization for H. inﬂuenzae
non-type b invasive disease/100 000 individuals increased,
indicating that the nominal increase in incidence was fol-
lowed by an increase in clinical burden.
Discussion
The present study shows an unambiguous increase in the
incidence of invasive disease caused by H. inﬂuenzae in south-
ern Sweden from 1997 to 2009. The observed increase is
explained by an increase in invasive disease caused by NTHi
and Hif, mainly in individuals >60 years of age, so this does
not imply that the vaccination campaign against Hib has been
unsuccessful. The incidence of invasive Hib disease in Sweden
remains stable at a very low level. However, the Hib cases
that were studied in detail were generally severe, with a high
TABLE 2. Disease severity, need for intensive care treatment, mortality and data on state of immunocompromise from a
total of 123 cases of invasive Haemophilus non-type b disease in Ska˚ne county 1997–2009
ACCP/SCCM category
NTHi (n = 101) Hif (n = 22)
Sepsis Severe sepsis Septic shock Sepsis Severe sepsis Septic shock
Patients (total n) 53 41 7 9 10 3
Immunocompromise per
sepsis category (n)a
20 15 3 5 1 1
Age >80 years per sepsis category (n)b 12 10 1 1 1 0
Need for intensive care (n) 20 8
28-day mortality (n) 8 3
1-year mortality (n) 29 5
Immunocompromisec (total n) 38 7
Acquired immunodeﬁciency (n) 25 (6 solid tumours and
19 blood cancers/myelomas)
5 (2 solid tumours
and 3 blood cancers)
Chronic disease (n) 9 (3 severe COPD, 3 dialysis
patients, 2 dysregulated diabetes
mellitus, and 1 heart disease)
1 (severe COPD)
Iatrogenic condition (n) 3 (1 organ transplant and
2 chemotherapy)
1 (chemotherapy)
ACCP/SCCM, American College of Chest Physicians/Society of Critical Care Medicine; COPD, chronic obstructive pulmonary disease; Hif, H. inﬂuenzae type f; NTHi, non-
typeable H. inﬂuenzae.
aAll ages of patients including individuals >80 years of age with immunocompromise.
bPatients >80 years of age with no sign of immunocompromise.
cIn addition to acquired immunodeﬁciency, chronic disease and iatrogenic conditions, one patient with a primary immunodeﬁciency was identiﬁed in the material. This particu-
lar patient with Good’s syndrome presented with an NTHi sepsis.
FIG. 3. The clinical burden from invasive Haemophilus inﬂuenzae
non-type b disease is increasing. The line with ﬁlled circles shows
total days of hospitalization of patients with invasive H. inﬂuenzae
non-type b disease per 100 000 individuals at risk in the county of
Ska˚ne (left y-axis). The number from 2002 is high because of two
cases with unusually long periods of hospitalization (>50 days). The
increase in hospitalization days during the years 1997–2009 was sig-
niﬁcant (p 0.046). For comparison, the black and grey bars show the
decreased average times of hospitalization/case due to pneumonia
and sepsis in the city of Malmo¨, Ska˚ne county 2001–2009 (right
y-axis).
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proportion of cases requiring intensive care treatment. The
ﬁndings therefore support continued vaccination against and
surveillance of Hib. Our study has a few limitations. We have
no data from before 1997 because of the unavailability of iso-
lates. However, there was still 13 years of observations,
allowing for trends to be observed. Furthermore, not all
recorded isolates could be retrieved and serotyped by PCR.
This was addressed by the performance of a secondary anal-
ysis excluding years and laboratories where <50% of isolates
could be retrieved.
In a recent European surveillance study [15], the total
incidence of invasive H. inﬂuenzae disease was 0.4–0.5 cases
per 100 000 individuals (2000–2006). The incidence varied
between regions from 0.02 cases per 100 000 individuals in
Italy to 1.0 case per 100 000 individuals in Norway. In our
study, the incidence of invasive H. inﬂuenzae disease in
Sweden almost reached 2.0 cases per 100 000 individuals,
numbers supported by Swedish national surveillance data
for 2007–2009 [7]. This suggests that Sweden has a current
incidence of invasive H. inﬂuenzae disease that is three-fold
higher than Europe in general, and 50- to 100-fold higher
than in Italy. These conﬂicting data may be the result of
actual, unexplained, differences in incidence, but could
also merely reﬂect problems with regional variations in
surveillance.
The present epidemiological observations are in line with
studies from other parts of the world. The epidemiology of
invasive Haemophilus disease in the post-Hib-vaccine era
seems to be shifting from Hib in children towards non-type
b strains in individuals >60 years of age [9,22]. Non-type b
strains now dominate in all age groups, including children
<5 years of age. We further identiﬁed that a major propor-
tion of invasive non-type b cases met the criteria for severe
disease. While Hib cases had the highest proportion of
severe disease (77%), as many as 47% of invasive NTHi and
59% of invasive Hif cases met the criteria of severe sepsis or
septic shock. Invasive disease by non-type b strains was not
conﬁned to immunocompromised patients or individuals of
extreme age; ﬁndings that are in contrast to the widely held
view that invasive disease by H. inﬂuenzae non-type b is mild
and opportunistic in nature. Invasive non-type b cases with a
severe clinical presentation often occurred in patients with
no evidence of immunocompromise, suggesting a signiﬁcant
impact of bacterial virulence in these cases. However, fatal
outcome was mainly observed in elderly or immunocompro-
mised patients, and this small group of cases seemed truly
opportunistic. Interestingly, the most common immuno
compromising conditions that are associated with invasive
Haemophilus disease were chronic lymphatic leukaemia and
multiple myeloma, highlighting the role of humoral immunity
in the control of H. inﬂuenzae disease [23,24]. Less efﬁcient
B-cell function is also a major part of immunosenescence
[25], which is intriguing considering the high incidence of
invasive Haemophilus disease in elderly individuals.
The increased incidence of invasive H. inﬂuenzae disease
is probably explained by a combination of contributing fac-
tors. Though the Swedish incidence of multiple myeloma or
chronic lymphatic leukaemia has not increased in recent
years [26], prolonged survival may have increased disease
prevalence. Another possible contributing factor is that the
total number of blood cultures taken in Sweden increased
during the study period. This may have led to the identiﬁ-
cation of more cases of pneumonia with bacteraemia. New
guidelines in Swedish pneumonia care stressing blood
culture as a quality indicator were introduced in 2007.
However, the proportion of severe invasive cases did not
decrease during the study period, indicating that modiﬁed
clinical routines cannot fully explain the observed increase
in incidence.
The introduction of the conjugated Hib vaccine has
decreased Hib airway carriage in children [27], and arguably
in adults. NTHi is a common colonizer of the human airway,
with or without airway disease, but information on nasopha-
ryngeal carriage rates of encapsulated Haemophilus other
than type b in healthy children is scarce. Interestingly, Strep-
tococcus pneumoniae and H. inﬂuenzae are niche competitors
in the upper airway and are suggested to be negatively cor-
related [28]. Pneumococcal vaccines may, however, affect
the future incidence of invasive H. inﬂuenzae disease because
an increased burden of H. inﬂuenzae disease following pneu-
mococcal vaccination has been suggested for other condi-
tions, such as otitis media [29]. In fact, a heptavalent
pneumococcal vaccine was introduced in the national vacci-
nation programme for children in Sweden in 2008 or 2009
depending of geographical region, and most probably had no
effect on the epidemiological results of the present study.
Another issue is that a conjugated pneumococcal vaccine
with H. inﬂuenzae protein D is now widely available, and
the effect of this vaccine on the occurrence of invasive
H. inﬂuenzae disease remains to be studied.
In conclusion, the present study demonstrates a statisti-
cally signiﬁcant increase in the incidence of invasive H. inﬂu-
enzae disease in southern Sweden 1997–2009, explained by
an increase in NTHi and Hif infections in individuals
>60 years of age. Strikingly, many patients with invasive non-
type-b disease presented no evidence of immunocompro-
mise, and a surprisingly high proportion of cases were severe
according to the ACCP/SCCM grading system. The results
call for continued surveillance and active monitoring of inva-
sive disease caused by H. inﬂuenzae.
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